Adverum Biotechnologies (ADVM) Projected to Post Quarterly Earnings on Monday

Adverum Biotechnologies (NASDAQ:ADVM) is expected to be issuing its quarterly earnings data before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($1.29) per share for the quarter.

Adverum Biotechnologies Price Performance

Shares of NASDAQ:ADVM opened at $4.61 on Friday. The company’s fifty day moving average price is $4.38 and its 200 day moving average price is $5.90. Adverum Biotechnologies has a 12 month low of $3.52 and a 12 month high of $18.00. The firm has a market capitalization of $95.90 million, a P/E ratio of -0.77 and a beta of 1.14.

Wall Street Analysts Forecast Growth

ADVM has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Adverum Biotechnologies in a research note on Tuesday, November 19th. StockNews.com lowered shares of Adverum Biotechnologies from a “hold” rating to a “sell” rating in a research note on Thursday, December 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Adverum Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.83.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.